Search Results

Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. They fail when the pressure of fundraising slowly starts reshaping how decisions are made , long before anyone notices that strategy has begun to drift. In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. Founders tell themselves that certain compromises are temporary, that clarity will return after the round closes. 👉 What actually happens is more subtle. Urgency replaces direction, and short-term signaling begins to outweigh long-term thinking. This is where most biotech startup fundraising mistakes are born, not from lack of intelligence or discipline, but from the belief that fundraising decisions exist outside the core strategy. 👉 In reality, every fundraising-driven adjustment leaves a structural mark on how the company operates, prioritizes, and allocates attention. Over time, these small shifts accumulate. Milestones are chosen for narrative strength rather than strategic leverage. Hiring decisions are pulled forward to support a story. Hard tradeoffs are delayed instead of resolved. 👉 None of these moves looks fatal on their own, yet together they quietly weaken even strong biotech startups. ✅ This post explores why fundraising mistakes have such a disproportionate impact on biotech companies, how these patterns emerge in otherwise well-run teams, and what founders can do to keep fundraising from taking control of their strategy. 👉 If you are preparing to raise, currently fundraising, or reflecting on a recent round, this is an opportunity to recognize where pressure may already be shaping decisions more than strategy should. Fundraising rarely breaks biotech startups overnight. It quietly reshapes decisions, long before the damage becomes visible. Fundraising turns strategy into reaction 👉 Fundraising rarely enters a biotech startup as a strategic decision-making framework. It enters as pressure. Pressure to show progress. Pressure to justify valuation. Pressure to appear confident about the future. And under pressure, even strong teams begin to confuse movement with direction. 👉 In early-stage biotech, this confusion is especially dangerous. Scientific progress already moves slowly, uncertainty is unavoidable, and timelines stretch far beyond what most investors are comfortable with. 👉 When fundraising begins, founders often respond by accelerating visible activity rather than strengthening underlying strategy. This is where one of the most common biotech startup fundraising mistakes takes root. Decisions stop being evaluated based on long-term leverage and start being filtered through a single question. Will this help the raise? 👉 When that question becomes dominant, strategy quietly shifts from intentional design to reactive justification. Teams begin to prioritize what can be explained easily over what actually matters most. Milestones are selected for narrative clarity rather than strategic necessity. Roadmaps bend toward what sounds fundable instead of what creates durable value. 👉 Over time, the company becomes highly responsive but increasingly misaligned. What makes this pattern so hard to catch is that it feels productive. Meetings increase. Slides improve. Activity intensifies. Yet clarity erodes, because reaction has replaced deliberate choice.   👉 Strong biotech startups do not fail at this stage because they stopped working hard. They fail because they stopped deciding with purpose. How biotech startup fundraising mistakes actually show up 👉 Fundraising mistakes rarely appear as obvious errors. In strong biotech startups, they surface as reasonable adjustments that seem aligned with reality. This is what makes them so difficult to recognize while they are happening. 👉 Under fundraising pressure, decision-making slowly shifts. Founders do not deliberately abandon strategy. Instead, they begin to evaluate choices through a narrower lens. What helps the raise starts to matter more than what strengthens the company. 👉 In practice, biotech startup fundraising mistakes most often show up as the following patterns: Milestones are chosen for narrative clarity rather than strategic leverage.   Experiments are prioritized because they fit a clean story, not because they meaningfully reduce scientific or commercial risk. Hiring decisions are accelerated to signal momentum.   Roles are added to demonstrate scale, even when the organization is not structurally ready to support them. Scientific priorities are reshaped to meet investor expectations.   Programs move forward because they sound fundable, not because the data justifies the timing. Hard strategic tradeoffs are postponed.   Founders delay narrowing focus, hoping clarity will emerge after the round instead of designing it upfront. Internal alignment weakens beneath visible progress.   Teams execute faster but understand less clearly why certain priorities exist, creating silent friction. 👉 Each of these decisions can be defended in isolation. The damage comes from their cumulative effect , when short-term fundraising logic quietly replaces deliberate strategy. 👉 This is why strong biotech startups often appear busiest right before they lose momentum. Activity increases, but clarity erodes , and the company becomes reactive instead of intentional. Clarity does not follow funding. Funding follows clarity. Why fundraising mistakes reshape the company before anyone notices Most biotech founders assume that fundraising mistakes show up as visible failures. A missed round. A rejected pitch. A broken investor process. In reality, the most damaging mistakes rarely appear at the surface. 👉 They take shape much earlier, inside the logic of everyday decisions, long before fundraising outcomes are known. Fundraising introduces a specific kind of cognitive pressure. It rewards confidence over uncertainty, clarity over complexity, and momentum over reflection. Under these conditions, decision making begins to shift subtly. Choices that simplify the story are favored over choices that preserve strategic truth. Decisions that reduce tension are prioritized over decisions that resolve it. 👉 The company does not become careless. It becomes selectively blind. As this pattern repeats, the organization adapts. Teams learn which questions are welcomed and which ones slow things down. Scientific nuance starts to feel inconvenient. Strategic debate is compressed into slide-friendly conclusions. 👉 What looks like alignment is often just the absence of friction, and friction disappears not because issues are solved, but because they are avoided. This is how biotech startup fundraising mistakes embed themselves into the operating system of the company. They are not single wrong calls, but accumulated shifts in how decisions are framed and justified. By the time founders sense that something feels off, the logic has already normalized. 👉 The company is still moving, still executing, but no longer questioning the direction with the same rigor. This is why strong biotech startups can lose their strategic center without any dramatic turning point. Nothing breaks all at once. Instead, clarity erodes quietly, decision by decision, under the assumption that everything will be fixed after the round closes. What actually prevents fundraising mistakes from taking over Most biotech founders try to solve fundraising-related problems by improving execution. Better decks. Clearer narratives. Tighter timelines. 👉 What they often miss is that execution quality does not protect strategy when the decision logic itself is unstable. The companies that avoid destructive fundraising mistakes do not do so because they raise faster or pitch better. They do it because they anchor fundraising inside a stronger strategic structure. 👉 That structure usually rests on a small number of non-negotiable principles. 1️⃣ They define strategic truth before investor truth. 👉 High-performing biotech teams are explicit about what must be true for the company to succeed, independent of how attractive that story sounds externally. Fundraising adapts to this reality, not the other way around. 2️⃣ They separate progress from presentation. 👉 These teams distinguish clearly between work that advances the company and work that merely explains it. Investor readiness never becomes the primary filter for scientific or organizational decisions. 3️⃣ They make hard tradeoffs early and visibly. 👉 Instead of postponing narrowing decisions until after a round, they resolve them upfront. This reduces internal ambiguity and prevents fundraising pressure from reopening questions that were already strategically settled. 4️⃣ They protect decision quality under pressure. 👉 As fundraising intensity increases, they slow down decision-making rather than accelerate it. Additional scrutiny is applied exactly where urgency would normally shortcut thinking. What unites these behaviors is not discipline for its own sake, but intent. Fundraising remains a tool, not a steering mechanism.  Strategy continues to shape decisions even when external pressure rises. ✅ This is the point where biotech startup fundraising mistakes stop accumulating. Not because risk disappears, but because decisions remain grounded in a framework that fundraising cannot easily distort. Strategic Takeaway 👉 Strong biotech startups are rarely destroyed by a single bad fundraising decision. They lose their edge when fundraising quietly becomes the logic behind everyday choices , replacing strategy with serving it. 👉 The difference between companies that survive fundraising pressure and those that drift is not discipline or ambition. It is whether decision-making remains anchored in a clear strategic framework before, during, and after the raise . Fundraising should amplify direction, not define it. When strategy leads, and fundraising follows, capital becomes leverage. When fundraising leads and strategy reacts, even strong biotech startups slowly lose coherence. ✅ The real work is not raising better. The real work is deciding clearly before pressure decides for you. Ready to Break Your Bottlenecks? If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational. It's strategic. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not just react to pressure. Whether you're refining your narrative, making tough trade-offs, or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start building the mindset your company actually needs.

involves alveolar differentiation of mammary epithelial cells (MECs), which is essential for breast milk assessing changes in cellular viability, lipid accumulation, and gene and protein expression of major milk We hypothesized that THC and CBD will negatively impact the synthesis of milk proteins and lipids, as Relative to control, 10μM THC and 10μM CBD reduced mRNA levels of milk proteins (CSN2 and WAP), lipid

September 2022 Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model of mild

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million , including an investment of $3 million from Virtus Inspire Venture Partners.

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million

The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in

December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Capital LLC, a healthcare-focused institutional investor, pursuant to which the Company agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares (“ADSs”) at a gross purchase price of $6.50 per ADS, which is equivalent to CHF 1.00 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered warrants to purchase up to 9,230,772 shares in the form of 1,538,462 ADSs (the “Unregistered Warrants”), as well as unregistered pre-funded warrants to purchase up to 5,478,570 shares in the form of 913,095 ADSs (the “Unregistered Pre-Funded Warrants” and together with the Unregistered Warrants, the “Warrants”) in a concurrent private placement. The Unregistered Warrants have an exercise price of $6.50 per ADS, will become exercisable in 60 days after their date of issuance and will expire six years from their date of issuance. The Unregistered Pre-Funded Warrants have been funded to the amount of $6.49 with $0.01 payable on exercise." Read more at the source #DrGPCR #GPCR #IndustryNews

July 2022 "Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Master Fund LTV, a healthcare-focused institutional investor, to sell 3,300,000 shares in the form of 550,000 American Depositary Shares (“ADSs”) at a gross purchase price of $1.70 per ADS, which is equivalent to CHF 0.27 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares in the form of 1,950,000 ADSs (the “Unregistered Pre-Funded Warrants”) at a funded amount of $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares in the form of 2,500,000 ADSs (the “Unregistered Warrants” and together with the “Unregistered Pre-Funded Warrants”, the “Warrants”) in a concurrent private placement. The Unregistered Warrants have an exercise price of $1.90 per ADS, will become exercisable in 60 days after their date of issuance and will expire five years from their date of issuance. " Read more at the source #DrGPCR #GPCR #IndustryNews

available high-affinity radioligands, but with the development of potent fluorescent probes, this gap can filled Soave M, Briddon SJ, Hill SJ, Stoddart LA. Stoddart LA, Kilpatrick LE, Briddon SJ, Hill SJ.

.; Robers, M. B.; Machleidt, T.; Wood, K. V.; Hill, S. J.; Pfleger, K. D. G.

Miles Thompson, Alexander Hauser, Caroline Gorvin et al. for their research on GPCR gene variants and Get started by filling out this form!

Biology - Tectonic Therapeutic Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan mechanosensing   GPCR Activation and Signaling A gain of function variant in RGS18 candidate for a familial mild

. ✅ Insider guidance  on how real teams decide which GPCR programs to advance or kill. Program Kill vs. Programs aren’t killed because of bad ideas—they’re paused when the chemical matter isn’t compelling

This week's highlight includes congrats to: Miles Thompson , Alexander Hauser , Caroline Gorvin ,   et Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million

GPCR Podcast, is filled with such moments, from bombing her first high school chemistry test to co-founding

GPCR Team This Week’s Highlights: Congratulations to Andrew Tobin for an incredible week filled with fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan

And misalignment kills momentum in slow, silent, irreversible ways. Fixing the Alignment Problem Before It Kills Your Strategy Biotech misalignment does not fix itself. And suddenly, it becomes obvious what to kill and what to scale. ✅ That’s the power of strategic realignment

Hauser on receiving 4.8 mill DKK from Carlsberg Foundation’s Semper Ardens: Accelerate programme.

Classified GPCR News from October 21st to 27th, 2024 Industry News UNC School of Medicine to Receive $3-Million fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Associate - Professor Graeme Milligan Chemistry GPCR Activation and Signaling A gain of function variant in RGS18 candidate for a familial mild

Brian Krumm and Bryan Roth studied CryoEM structures of adhesion in GPCR CD97, filling gaps. For those who joined any of our symposium sessions, we kindly request a moment of your time to fill out Adhesion GPCRs CryoEM structures of adhesion in GPCR CD97: Filling in some of the gaps GPCR Activation

Take 2 minutes to fill out this survey and let us know what you liked, what you didn’t, and what we can GPCR University have been filled! Thank you for the overwhelming response. Please fill out the waitlist form. We'll let you know if any spots become available. Dr.

Graeme Milligan for receiving the Order of British Empire from King Charles III in recognition of his If you're interested in presenting a poster, simply fill out the submission form and submit a 1-minute Graeme Milligan was awarded the Order of British Empire by King Charles III for services to Biochemical

—Alessandro Nicoli A New Era of GPCR Research AlphaFold didn’t just fill a gap—it shifted the focus of

3 out of the 25 spots have been filled! Team Registrations are also available! To begin, please fill out this form!

science and operational strategy, revealing why throwing more money and people at a problem is a multi-million GPCR Premium Membership Gives You an Edge In a world filled with noise, Dr.

This session unpacks how persistent binding can either accelerate your program—or quietly kill it. mechanisms are designed, not discovered by accident , they become strategic levers: Selective, durable tumor kill

In this context, mutagenesis has emerged as an "old-school" but essential technology to fill these knowledge cryo-electron microscopy have deepened our understanding of ligand-receptor interactions, mutagenesis fills

cell type–specific roles for C3aR in regulating innate immune cell inflammatory state, antimicrobial killing